CompletedPhase 2NCT04919642
Study to Evaluate the Efficacy and Safety of TT-00420 (Tinengotinib) in Cholangiocarcinoma
Studying Cholangiocarcinoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- TransThera Sciences (Nanjing), Inc.
- Principal Investigator
- Milind Javle, MD, M.DM.D. Anderson Cancer Center
- Intervention
- TT-00420(drug)
- Enrollment
- 55 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2021 – 2024
Study locations (30)
- Providence Cancer Center, Anchorage, Alaska, United States
- City of Hope, Duarte, California, United States
- University of California, Los Angeles, School of Medicine, Santa Monica, California, United States
- USO Oncology Network- Rocky Mountain Cancer Centers, Denver, Colorado, United States
- Mount Sinai Medical Center, Miami Beach, Florida, United States
- University of Chicago Medical Center - Duchossis Center for Advanced Medicine, Chicago, Illinois, United States
- University of Maryland - Marlene and Stewart Greenebaum Cancer Center, Baltimore, Maryland, United States
- University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States
- Henry Ford Health Center, Detroit, Michigan, United States
- Mayo Clinic, Rochester, Minnesota, United States
- Comprehensive Cancer Center of Nevada, Las Vegas, Nevada, United States
- Summit Medical Group - Florham Park Campus, Florham Park, New Jersey, United States
- Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States
- Ruttenberg Treatment Center - Mount Sinai, New York, New York, United States
- USOR Oncology Network- New York Oncology, New York, New York, United States
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04919642 on ClinicalTrials.govOther trials for Cholangiocarcinoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07478523FAPI-PET Value for the Initial Screening of Pancreatic and Biliary CancersUniversity Hospital, Bordeaux
- RECRUITINGNANCT07476651Scout Dose of Resin MicrospheresSeoul National University Hospital
- RECRUITINGPHASE2NCT06728410A Phase II Study of Pemigatinib Plus Durvalumab in Previously Treated Advanced Intrahepatic Cholangiocarcinoma Patients With FGFR-2 Fusion or RearrangementMehmet Akce
- RECRUITINGPHASE2NCT07223307REGULUS: MRI-guided Adaptive SABR for Liver CancersStanford University
- RECRUITINGPHASE2NCT07201519Study of Safety/Feasibility of a Hybrid Model of Tertiary and Community Delivery of Hepatic Artery Infusion ChemotherapyMichael J Cavnar, MD
- RECRUITINGPHASE2NCT07260175Phase II Study Evaluating Ivosidenib Maintenance After SOC Adjuvant Chemotherapy in Curative mIDH1 CholangiocarcinomaInstitut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
- RECRUITINGNANCT06735560Study Assessing PET Imaging With Zirconium-labelled Girentuximab in Patients With HCC, ICC or NENNantes University Hospital
- RECRUITINGNCT07206355In-Depth Characterisation of Biliary Strictures and Hepato-Pancreato-Biliary Focal Lesions for Development of New Technologies to Tackle Hepato-Pancreato-Biliary CancersUniversity of Nottingham